Evidence map›Paper›PMID 42901952›Full record

ArticleNPJ biofilms and microbiomes2026

Recovering anaerobic bacterial genomes in saliva, tumour and blood whole genome sequencing data from patients with prostate cancer.

A Gihawi, A Bampalis, S Subramanian, Pan Prostate Cancer Group, G S Bova, A Butler, N M Corcoran, F Favero, V Gnanapragasam, A Hamid and 39 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

A GihawiDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK. A.Gihawi@uea.ac.uk.ORCID http://orcid.org/0000-0002-3676-5561
A BampalisDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.
S SubramanianDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.
Pan Prostate Cancer Group
G S BovaProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
A ButlerWellcome Sanger Institute, Cambridge, UK.
N M CorcoranDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.
F FaveroBiotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
V GnanapragasamCambridge Prostate Cancer Research and Clinical Trials Group, University of Cambridge & Cambridge University Hospitals NHS Trust S2, Cambridge Biomedical Campus, Cambridge, UK.
A HamidDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.
C JungMelbourne Bioinformatics, The University of Melbourne, Parkville, VIC, Australia.
Z Kote JaraiRoyal Marsden NHS Foundation Trust, London, UK.
G LeemanWellcome Sanger Institute, Cambridge, UK.
M LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
J ReimandComputational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada.
A SahliManchester Cancer Research Centre, The University of Manchester, Manchester, UK.
T SchlommDepartment of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
T N YamaguchiJonsson Comprehensive Cancer Centere, University of California-Los Angeles, Los Angeles, CA, USA.
J WeischenfelftBiotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
C HovensDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.
B PopeDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.
R BristowChristie NHS Foundation Trust, Manchester, UK.
M N BrookThe Institute of Cancer Research, London, UK.
K C L ChengComputational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada.
E G GirmaBiotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
A J GruberDepartment of Biology, University of Konstanz, Konstanz, Germany.
H H HePrincess Margaret Cancer Centre, University Health Network, Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
E L ImadaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
G M JakobsdottirDivision of Cancer Sciences, The University of Manchester, Manchester, UK.
F KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
P LutsikDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
L MarchionniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
R MolaniaThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
A T PapenfussThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
D PellegrinaComputational Biology Program, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada.
L R QueirozDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
T RauschGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
B RobinsonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
C ZanettiniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
K D SørensenDepartment of Clinical Medicine, Aarhus University & Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
P LamyDepartment of Clinical Medicine, Aarhus University & Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
G Cancel-TassinCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), Paris, France.
O CussenotCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), Paris, France.
R A EelesRoyal Marsden NHS Foundation Trust, London, UK.
N AnnelsUniversity of Surrey, Surrey, UK.
V M HayesDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.
R HurstDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.
C S CooperDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.
D S BrewerDepartment of Metabolic Health, Norwich Medical School, University of East Anglia, University of East Anglia, Norwich, UK.

Funding

Prostate Cancer UK MA-TIA23-002, MA-ETNA19-003, RIA15-ST2-029 and TLD-CAF22-011
6 · The paper itself

Abstract

Microbial constituents in the gastrointestinal tract, the urine and prostate tissue are being linked with clinical differences in prostate cancer, and a recent meta-analysis has linked periodontal disease to this cancer. Several hypotheses exist regarding how specific bacteria can contribute towards the development of prostate cancer. Recovering microbial genomes, and their genomic features, from clinical samples and investigating fine-scale taxonomy is a critical first step in investigating causality. Here, we describe the microbial diversity of samples associated with prostate cancer. Metagenomic assembly of non-human reads from the PanProstate Cancer Group, derived from blood, saliva samples and prostate tissue whole-genome data (N = 247), successfully reconstructed 249 highly complete bacterial genomes, predominantly from oral samples. Our data, reveals eighteen bacterial species from the oral cavity without species level classification, while demonstrating a wide range of known species. This approach enables us to gain additional insights of the microbes in cancer patients at no additional sequencing cost and has the potential to reveal new links that could improve our understanding of cancer initiation and development.

Indexed as

Bacteria, AnaerobicBloodGenome, BacterialProstatic NeoplasmsSalivaHumansMaleMetagenomicsPhylogenyWhole Genome Sequencing

Identifiers

PMID42901952
PMCPMC13683340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.